COMPANY

Zai Lab

HQ: Cambridge, MA source · zailaboratory.com ↗ · China

Keywords: oncology neurology immunology ovarian cancer antibody myasthenia gravis chronic inflammatory demyelinating polyneuropathy Eczema Chronic Obstructive Pulmonary Disease Asthma Idiopathic Pulmonary Fibrosis ZL-3101 ZL-2102

Location: Cambridge, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$200.0MRaised (2 yrs)2Trials (company is sponsor)

Timeline

Nov 14, 2024 Raise Follow-on offering: $200M (total, as published), announced Nov 14, 2024. Source: SEC filing. source ↗
Apr 26, 2017 Trial start Phase 2: Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema source ↗
2015-03 Trial start Phase 1: Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects source ↗

Funding

Raised: $200.0M. Last 2 years.

Nov 14, 2024 Follow-on offering: $200M (total, as published), announced Nov 14, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT03134352	Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema	Phase 2	Completed	Apr 26, 2017	May 25, 2018 (actual)
NCT02397005	Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects	Phase 1	Unknown status (ClinicalTrials.gov)	2015-03	2016-04 (actual)